PD13 Severe cutaneous manifestations in an Indian child with X-linked dominant erythropoietic protoporphyria

نویسندگان

چکیده

Abstract Erythropoietic protoporphyria (EPP) is usually caused by autosomal dominant mutations in FECH: raised protoporphyrin levels cause itching, burning and erythema after sun exposure, with facial scarring sometimes liver damage. We report a child the much rarer X-linked form (XLDPP) consider reasons for his unusually severe features. A 4-year-old boy living India presented long-standing erosions on face sides of feet, marked distal onycholysis subungual hyperkeratosis affecting all nails, suggestive pachyonychia congenita (PC). There was no relevant family history or parental consanguinity. He anaemic (haemoglobin 7.2 g dL−1). Genetic testing revealed variants PC genes, but there hemizygous deletion ALAS2, c.1706_1709del (p.Glu569GlyfsT er24) reported recurrently XLDPP. Further review photosensitivity, low vitamin D3 enzymes. Measurement erythrocyte not available, XLDPP diagnosed basis abnormalities, probable photo-onycholysis genetic testing. ALAS2 encodes 5-aminolaevulinate synthase, first enzyme haem synthetic pathway. Most block haemoglobin production resulting sideroblastic anaemia. However, specific deletions, including this one, activate pathway, increasing to higher than what can be used haematopoiesis. The manifestations therefore resemble EPP: accumulation former increased latter its conversion haem. Iron deficiency, common Indian children, reduces consequently utilization, potentially exacerbating In previous patient anaemia due gastrointestinal bleeding, iron therapy successfully lowered red cell (Whatley SD, Ducamp S, Gouya L et al. C-terminal deletions gene lead gain function without anemia overload. Am J Hum Genet 2008; 83:408–14). Nail dystrophy has previously been appearance here consistent whose feet are always exposed sandals. delay diagnosing photosensitivity severity skin changes attributed difficulty interpreting symptoms young children local conditions where exposure unavoidable. Management involves therapy, photoprotection, monitoring counselling; female carriers may also have symptoms. grateful national experts helpful discussion case.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria.

Erythropoietic protoporphyria (EPP) results from deficiency of ferrochelatase (FECH). Accumulation of protoporphyrin IX causes life-long acute photosensitivity. Microcytic anemia occurs in 20% to 60% of patients. We investigated 178 patients with dominant EPP confirmed by molecular analysis. Erythropoiesis was impaired in all patients; all had a downward shift in hemoglobin (Hb), and the mean d...

متن کامل

Severe cutaneous manifestations in a child with refractory Kawasaki disease.

tosus. Ann Rheum Dis 2005;64:947–50. 9. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24. 10. Svensson B, Schaufelberger C, Teleman A, Theander J. Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rh...

متن کامل

Erythropoietic protoporphyria

Erythropoietic protoporphyria (EPP) is an inherited disorder of the haem metabolic pathway characterised by accumulation of protoporphyrin in blood, erythrocytes and tissues, and cutaneous manifestations of photosensitivity. EPP has been reported worldwide, with prevalence between 1:75,000 and 1:200,000. It usually manifests in early infancy upon the first sun exposures. EPP is characterised by...

متن کامل

Afamelanotide for Erythropoietic Protoporphyria.

BACKGROUND Erythropoietic protoporphyria is a severe photodermatosis that is associated with acute phototoxicity. Patients with this condition have excruciating pain and a markedly reduced quality of life. We evaluated the safety and efficacy of an α-melanocyte-stimulating hormone analogue, afamelanotide, to decrease pain and improve quality of life. METHODS We conducted two multicenter, rand...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: British Journal of Dermatology

سال: 2023

ISSN: ['1365-2133', '0007-0963']

DOI: https://doi.org/10.1093/bjd/ljad113.351